WHO WE ARE
BDI, a 501(c)(3) nonprofit organization located in San Diego, California, focuses on addressing the social, emotional, and psychological barriers to living a long and healthy life with diabetes. To better understand and overcome these obstacles, BDI is actively engaged in research examining the psychological aspects of diabetes and evaluating innovative behavioral interventions. In addition, BDI directly offers an array of unique, behaviorally-oriented products and services for: people with type 1 diabetes; people with type 2 diabetes; parents of children and teens with diabetes; spouses and partners of people with diabetes; and interested health care professionals. Products and services include print materials; online courses and modules, face-to-face workshops and seminars, professional training programs, and an online library of resources.
We invite you to explore the resources available to you from BDI. We also welcome your suggestions for additional resources that might be added to our web site. Thank you!
BDI will host our next case consultation meeting (for mental health professionals working in the field of diabetes). Contact us at email@example.com if you are in the greater San Diego area and would like further information about this program and about our future meetings.
December 7, 2020
December 8, 2020
December 12, 2020
Welcome to BDI’s December update!
December 7: BDI will host our next, San Diego-wide, case consultation meeting (for mental health professionals working in the field of diabetes). Contact us at firstname.lastname@example.org if you are in the greater San Diego area and would like further information about this program and about our future meetings.
December 8: Dr. Guzman will be the featured speaker for the American Diabetes Association’s Ask The Expert event.
December 12: It is time for Taking Control of Your Diabetes’ (TCOYD) Virtual Conference and Health Fair: Home for the Holidays. This is an online interactive experience that is open to all people with diabetes everywhere. It will feature an extraordinary group of diabetes healthcare professionals, including our own Dr. Polonsky as one of the featured speakers.
New study opportunity for people with type 2 diabetes and type 1 diabetes:
Are you using Dexcom Clarity? Would you be willing to let us interview you on a private, confidential video call? We are looking for a few people with type 1 diabetes and a few people with type 2 diabetes who might be willing to participate. This project focuses on learning more about how people think about and use Dexcom Clarity, and how its use has affected them. Might you be interested? As a study participant, we will be providing you with a small payment for your help. The formal announcement is not yet available, but send us your contact information to email@example.com, and tell us whether you have type 1 diabetes or type 2 diabetes. We will then send along the full details as soon as they are available.
Professional training programs beginning in February:
February 19. Save the date! “Understanding and Addressing Problematic Medication Taking in Diabetes” is a live, virtual one-day training program for healthcare professionals.
This will be the first of four one-day training programs in 2021. Registration will be open soon, and you can sign up here to be notified when registration opens.
Three new publications:
BDI staff were proud to serve as co-authors on three new, peer-reviewed scientific publications.
The first two papers highlight new findings regarding CGM: “Majority of people with type 1 diabetes and multiple daily insulin injection benefit by using Continuous Glucose Monitoring: An analysis based on the GOLD randomised trial (GOLD-5)” and “Sustained Intensive Treatment and Long-term Effects on HbA(1c) Reduction (SILVER Study) by CGM in People with Type 1 Diabetes Treated With MDI”
The third paper describes the quality of life benefits resulting from Onduo’s virtual diabetes clinic: “Impact of Participation in a Virtual Diabetes Clinic on Diabetes-Related Distress in Individuals with Type 2 Diabetes”